Yatharth Hospital & Trauma Care Services Limited announces an acquisition

The full ₹3,150 Cr issue would move Yatharth from 0.09x net debt-to-equity to approximately –0.59x on a pre-deployment, fully funded pro-forma basis—i.e., a net-cash position. This assumes the entire issue proceeds are received in cash and added to equity, before the funds are spent.

• Latest reported net debt: ₹175.17 Cr
• Latest reported total equity: ₹1,875.7 Cr
• Pro-forma net debt: ₹175.17 Cr – ₹3,150 Cr = –₹2,974.83 Cr
• Pro-forma equity: ₹1,875.7 Cr + ₹3,150 Cr = ₹5,025.7 Cr
• Pro-forma net debt-to-equity: –₹2,974.83 Cr / ₹5,025.7 Cr = –0.59x

The starting figures are from Q2 FY27 consolidated data, where reported net debt-to-equity was 0.09x. ^{[1] [2] [3]}

Utilization split

The latest utilization schedule specifies:

• ₹2,362.50 Cr for hospital-network expansion and development, with a three-year utilization timeline. This is the identifiable expansion bucket relevant to increasing bed capacity. ^[4]
• ₹787.50 Cr for other general corporate purposes. ^[4]
• Separately earmarked debt reduction: not confirmed. The cited utilization schedule does not assign a standalone amount to debt repayment; therefore, the ₹787.50 Cr residual should not automatically be treated as debt reduction. ^[4]

Accordingly, the –0.59x figure is a gross capital-infusion pro forma, not necessarily the post-utilization leverage ratio. Once ₹2,362.50 Cr is deployed into expansion and the balance is spent, the eventual net debt-to-equity ratio will depend on how much—if any—of the ₹787.50 Cr is actually applied to debt repayment and on the timing of the warrant proceeds. The transaction is structured with equity shares and warrants; management had indicated an initial tranche of ₹1,750 Cr, with the balance linked to the subsequent warrant funding. ^[5]

Rasmalai Limited is to hold 24.87% of Yatharth Hospital’s post-issue share capital on a fully diluted basis following the preferential issue. ^[6]

The CCI approval disclosure does not set out any specific board representation rights or restrictive covenants governing Yatharth’s future capital raises. Accordingly, whether the underlying preferential issue or investment agreement contains investor board-nomination rights, veto matters, pre-emptive rights, or capital-raising restrictions could not be confirmed from the cited CCI filings. The filing only confirms that the transaction remains subject to other applicable regulatory and statutory requirements. ^[6]

The ₹3,150 Cr infusion is roughly ten times Yatharth’s current annual capex run-rate. However, the facility-level capex required for the recently commissioned or under-construction NCR assets could not be confirmed from the cited material, so the infusion cannot be directly matched against those projects individually.

The headline ₹3,150 Cr is a total commitment, not necessarily immediate cash. The proposed issue comprises ₹1,283.33 Cr of equity shares paid upfront and ₹1,866.67 Cr of warrants, of which 25% is payable upfront and the balance on exercise ^[9]. That implies initial cash of approximately ₹1,750 Cr, with the remaining approximately ₹1,400 Cr dependent on warrant exercise, derived from the stated issue structure ^[9]. Even the initial tranche is about 5.5 times FY26 capex, derived from ₹1,750 Cr and ₹316.54 Cr ^{[9] [8]}.

Analytical implication: the capital is large enough to fund a multi-year expansion programme rather than merely sustain the existing capex cadence. But ₹2,362.5 Cr is described as hospital-network expansion and development, not as a project-by-project NCR construction budget. The cited material does not quantify the capex of each recently commissioned or under-construction NCR facility; those requirements could not be confirmed. Accordingly, the appropriate conclusion is that the infusion provides substantial headroom relative to historical spending, while the precise surplus or shortfall against NCR project needs remains unresolved.